Brief: LENZ Therapeutics Announces Nmpa Submission Of New Drug Application For LNZ100 In China For The Treatment Of Presbyopia
28/07/2025 14:02
July 28 (Reuters) - Lenz Therapeutics Inc LENZ.O: LENZ THERAPEUTICS ANNOUNCES NMPA SUBMISSION OF NEW DRUG APPLICATION FOR LNZ100 IN CHINA FOR THE TREATMENT OF PRESBYOPIA Source text: ID:nGNX3k7gVd Further company coverage: LENZ.O ((Reuters.Briefs@thomsonreuters.com;))